Bio Saga Headlines

Bio Saga

Tuesday, February 15, 2011


Initiating sequencing of a set of 60 closely related human genomes to identify novel genetic information relevant to cancer, metabolic and neurological disorders. Through this project, Avesthagen intends to establish a direct link between genes, genetics and the disorders themselves. 

The study, led by Avesthagen, a life sciences company based in Bangalore, is being carried out in partnership with Genome Enterprise Limited, a subsidiary of The Genome Analysis Centre (TGAC) on the Norwich Research Park.. The TGAC team, specialists in DNA sequencing and bioinformatics, will use the SOLiD™ 4 next generation sequencing platform from Applied Biosystems, part of Life Technologies, to generate draft sequence, and will collaborate with the Avesthagen’s own bioinformatics experts to analyze and interpret the sequence data
It is known that many genes on the human chromosomes may be involved during the manifestation of the above disorders. However, the power of present technologies to link the causative genes to disorders is limited. Sequencing the 60 genomes for different disorders will be groundbreaking as analysis of the mammoth 10 terabytes of data generated will enable scientists to discover novel causative genes on the chromosomes which may be shown to be indicative of occurrence of cancer, metabolic and neurological disorders. Once completed there will be better understanding of the genetics underlying the diseases. The study will help in identifying new and better drugs, specific for the above-mentioned disorders. The discovery will lead to identifying bio molecules for the accurate prediction of the disease manifestation.

Avesthagen aims to facilitate predictive, preventive and personalized approach for diagnosis and treatment for cancer, metabolic and neurological disorders. Avesthagen has adopted a holistic approach applying state-of-the-art technology to not only come up with therapies, but go one step further in developing the most sensitive means of prediction and diagnosis. In its development program Avesthagen’s biopharmaceutical division also has a strong focus and drug portfolio pipeline on oncology and other above-mentioned disorders. Another major breakthrough by the company, in this field is the discovery of novel signature metabolites for Cancer, which is currently in the phase of clinical validation.

No comments:

Life Science and Informatics

What is this?
is this a new industry?
or a old wine in a new bottle?

Well Life Sciences and Informatics can be anything form computational biology, all omes and omics, core bioinformatics to curation and literature mining, database creation, in the area of biology, chemistry , bio-chem space.

There are number of companies in India and bangalore is the forefront as a major bio-cluster with 20 to 30 companies in this sphere.

now how good are these companies doing?
how good are they in terms of the international markets and how profitable is their business?
what do they do?
their clients?

These are some interesting things that could be discussed in this blog page...

Tag It